Differences and application value of plasma bile acids in tumors of the liver

Ru JIA; Pingping ZHANG; Yuan YUAN; Yiyang HU; Qin FENG

doi:10.12449/JCH241018

Volume 40 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(10): 2042-2048

PDF( 1078 KB)

Differences and application value of plasma bile acids in tumors of the liver

DOI: 10.12449/JCH241018

Ru JIA^1a,
Pingping ZHANG^1a,
Yuan YUAN^2a,
Yiyang HU^{2b, 3, 4},
Qin FENG^{1b, 2b, 3, 4
,
,
,}

1a.
Department of Oncology，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
1b.
Technical Experimental Center，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
2a.
School of Integrative Medicine，Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
2b.
Institute of Liver Diseases，Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
3.
Shanghai Key Laboratory of Traditional Chinese Medicine，Shanghai 201203，China
4.
Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China

Research funding:

National Natural Science Foundation of China (82104619);

Shanghai Municipal Health Commission Health Industry Clinical Research Project (20214Y0455);

Project under Budget of Shanghai University of Traditional Chinese Medicine (2021LK105)

More Information

Corresponding author: FENG Qin， fengqin@shutcm.edu.cn （ORCID： 0000-0002-4641-1636）
Received Date: 2024-01-24
Accepted Date: 2024-04-15
Published Date: 2024-10-25

Abstract

Abstract

Objective To investigate the levels of plasma bile acids （BA） in patients with primary liver cancer （PLC） or metastatic liver cancer （MLC） and their correlation with clinical indicators， as well as the value of plasma BAs combined with alpha-fetoprotein （AFP） in the diagnosis of PLC. Methods This study was conducted among 75 patients with PLC and 79 patients with MLC who attended Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2020 to September 2021 and had a confirmed diagnosis based on histopathological and imaging findings. Peripheral blood samples were collected from all patients， and serum and plasma were separated. Colorimetry and chromatography were used to measure biochemical parameters； electrochemiluminescence immunoassay was used to measure the levels of tumor markers； liquid chromatography-tandem mass spectrometry was used to measure the content of BA. The t-test was used for comparison of normally distributed continuous data， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data； the Spearman’s coefficient was used for correlation analysis； the receiver operating characteristic （ROC） curve was used to evaluate clinical diagnostic efficacy. Results The PLC group had significantly lower levels of total cholesterol， triglyceride， low-density lipoprotein cholesterol， and apolipoprotein B than the MLC group （U=1 598， 1 255， 909， and 889， all P<0.05）. Compared with the MLC group， the PLC group had a significantly higher level of AFP and a significantly lower level of carcinoembryonic antigen （U=1 873 and 926， both P<0.05）. Compared with the MLC group， the PLC group had significantly higher levels of TBA， CA， CDCA， UDCA， TCA， TCDCA， GCA， GCDCA， TUDCA， and GUDCA and a significantly lower level of DCA （all P<0.05）. In the total population， the levels of TBA， CDCA， GCA， GCDCA， GUDCA， TCA， TCDCA， and TUDCA were significantly positively correlated with the level of AFP （all P<0.05）. In the patients with PLC， the levels of GCA， TCA， TCDCA， and TUDCA were significantly positively correlated with the level of AFP （all P<0.05）. Combined measurement of AFP+TCA+GCA+TCDCA had an area under the ROC curve of 0.822 （95% confidence interval： 0.746‍ ‍—‍ ‍0.898， P<0.000 1）， suggesting that it had the highest diagnostic efficacy. Conclusion There are significant differences in the levels of plasma BA between the patients with PLC and those with MLC， and the differentially expressed BAs are closely associated with liver function impairment and the increase in AFP. BAs combined with AFP has a better clinical value in the diagnosis of PLC.
- Bile Acids and Salts,
- Liver Neoplasms,
- Neoplasm Metastasis

FullText(HTML)

References(31)

References

[1]	JIA W, XIE GX, JIA WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 2): 111- 128. DOI: 10.1038/nrgastro.2017.119.
[2]	CHÁVEZ-TALAVERA O, TAILLEUX A, LEFEBVRE P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 7): 1679- 1694.e3. DOI: 10.1053/j.gastro.2017.01.055.
[3]	SMIRNOVA E, MUTHIAH MD, NARAYAN N, et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD[J]. Hepatology, 2022, 76( 6): 1811- 1824. DOI: 10.1002/hep.32568.
[4]	CHEN T, WANG L, XIE G, et al. Serum bile acids improve prediction of Alzheimer's progression in a sex-dependent manner[J]. Adv Sci(Weinh), 2024, 11( 9): e2306576. DOI: 10.1002/advs.202306576.
[5]	SONG WS, PARK HM, HA JM, et al. Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma[J]. Sci Rep, 2018, 8( 1): 11088. DOI: 10.1038/s41598-018-29445-z.
[6]	JI SY, LIU QX, ZHANG SH, et al. FGF15 activates hippo signaling to suppress bile acid metabolism and liver tumorigenesis[J]. Dev Cell, 2019, 48( 4): 460- 474. e 9. DOI: 10.1016/j.devcel.2018.12.021.
[7]	SUN RQ, ZHANG ZY, BAO RX, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis[J]. J Hepatol, 2022, 77( 2): 453- 466. DOI: 10.1016/j.jhep.2022.02.030.
[8]	LIU ZR, JIA XD, LU YY. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. J Clin Hepatol, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038. 刘哲睿, 贾晓东, 陆荫英. 肝细胞癌相关胆汁酸代谢失衡及调控机制的研究进展[J]. 临床肝胆病杂志, 2021, 37( 3): 690- 694. DOI: 10.3969/j.issn.1001-5256.2021.03.038.
[9]	SYDOR S, BEST J, MESSERSCHMIDT I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC[J]. Clin Transl Gastroenterol, 2020, 11( 3): e00131. DOI: 10.14309/ctg.0000000000000131.
[10]	PETRICK JL, FLORIO AA, KOSHIOL J, et al. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies[J]. Int J Cancer, 2020, 147( 10): 2743- 2753. DOI: 10.1002/ijc.33051.
[11]	LI YY, LI JJ, SHI HF, et al. Advances in imaging research on source identification of primary liver metastases[J]. J Clin Radiol, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007. 黎玉莹, 李晶晶, 石海峰, 等. 肝转移瘤原发灶来源鉴别的影像学研究进展[J]. 临床放射学杂志, 2023, 42( 5): 878- 881. DOI: 10.13437/j.cnki.jcr.2023.05.007.
[12]	JIA W, WEI ML, RAJANI C, et al. Targeting the alternative bile acid synthetic pathway for metabolic diseases[J]. Protein Cell, 2021, 12( 5): 411- 425. DOI: 10.1007/s13238-020-00804-9.
[13]	LI TG, CHIANG JYL. Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacol Rev, 2014, 66( 4): 948- 983. DOI: 10.1124/pr.113.008201.
[14]	WANG CZ, YANG MY, ZHAO JF, et al. Bile salt(glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234( 7): 10899- 10906. DOI: 10.1002/jcp.27905.
[15]	MA C, HAN MJ, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360( 6391): eaan5931. DOI: 10.1126/science.aan5931.
[16]	SARKAR J, AOKI H, WU RR, et al. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis[J]. Ann Surg Oncol, 2023, 30( 3): 1630- 1641. DOI: 10.1245/s10434-022-12806-4.
[17]	CHENG P, WU JW, ZONG GF, et al. Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver[J]. Pharmacol Res, 2023, 188: 106643. DOI: 10.1016/j.phrs.2022.106643.
[18]	HAN J, QIN WX, LI ZL, et al. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Clin Chim Acta, 2019, 488: 68- 75. DOI: 10.1016/j.cca.2018.10.039.
[19]	LUO P, YIN PY, HUA R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma[J]. Hepatology, 2018, 67( 2): 662- 675. DOI: 10.1002/hep.29561.
[20]	XIAN LF, FANG LT, LIU WB, et al. Epidemiological status, main pathogenesis and prevention and control strategies of primary liver cancer[J]. Chin J Oncol Prev Treat, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13. 鲜林峰, 方乐天, 刘文斌, 等. 原发性肝癌流行现状、主要发病机制及防控策略[J]. 中国癌症防治杂志, 2022, 14( 3): 320- 328. DOI: 10.3969/j.issn.1674-5671.2022.03.13.
[21]	The Society of Liver Cancer, China Anti-Cancer Association. CACA guidelines for holistic integrative management of cancer-liver cancerpart[J/CD]. J Multidiscip Cancer Manag Electron Version, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06. 中国抗癌协会肝癌专业委员会. 中国肿瘤整合诊治指南(CACA)-肝癌部分[J/CD]. 肿瘤综合治疗电子杂志, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.
[22]	TIAN CX, ZHAO L. Epidemiological characteristics of colorectal cancer and colorectal liver metastasis[J]. Chin J Cancer Prev Treat, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12. 田传鑫, 赵磊. 结直肠癌及结直肠癌肝转移流行病学特点[J]. 中华肿瘤防治杂志, 2021, 28( 13): 1033- 1038. DOI: 10.16073/j.cnki.cjcpt.2021.13.12.
[23]	WANG ZJ, KIM SY, TU W, et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment[J]. Cell Metab, 2023, 35( 7): 1209- 1226. e 13. DOI: 10.1016/j.cmet.2023.04.013.
[24]	XIAO JF, VARGHESE RS, ZHOU B, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J]. J Proteome Res, 2012, 11( 12): 5914- 5923. DOI: 10.1021/pr300673x.
[25]	ZENG HW, UMAR S, RUST B, et al. Secondary bile acids and short chain fatty acids in the colon: A focus on colonic microbiome, cell proliferation, inflammation, and cancer[J]. Int J Mol Sci, 2019, 20( 5): 1214. DOI: 10.3390/ijms20051214.
[26]	LI JY, GILLILLAND M 3rd, LEE AA, et al. Secondary bile acids mediate high-fat diet-induced upregulation of R-spondin 3 and intestinal epithelial proliferation[J]. JCI Insight, 2022, 7( 19): e148309. DOI: 10.1172/jci.insight.148309.
[27]	CHEN TL, XIE GX, WANG XY, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Mol Cell Proteomics, 2011, 10( 7): M110.004945. DOI: 10.1074/mcp.M110.004945.
[28]	COLLINS SL, STINE JG, BISANZ JE, et al. Bile acids and the gut microbiota: Metabolic interactions and impacts on disease[J]. Nat Rev Microbiol, 2023, 21( 4): 236- 247. DOI: 10.1038/s41579-022-00805-x.
[29]	ZHANG YF, LI MC. Application value of chitosanase 3-like protein 1, alpha-fetoprotein, glycoactrin 19-9, glutamyltranspeptidase in the early diagnosis of primary liver cancer[J]. Chin J Health Lab Technol, 2023, 33( 4): 467- 470. 张艳芬, 李明才. 血清壳多糖酶3样蛋白1、甲胎蛋白、糖类抗原19-9及谷氨酰转肽酶在原发性肝癌早期诊断中的应用价值[J]. 中国卫生检验杂志, 2023, 33( 4): 467- 470.
[30]	YANG YP, XU EJ, WANG XX, et al. The value of GNB4 and Riplet gene methylation detection in the diagnosis of primary liver cancer[J]. Acta Univ Med Anhui, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028. 杨玉萍, 徐恩君, 汪轩轩, 等. GNB4和Riplet基因甲基化检测在原发性肝癌诊断中的价值研究[J]. 安徽医科大学学报, 2024, 59( 2): 357- 362. DOI: 10.19405/j.cnki.issn1000-1492.2024.02.028.
[31]	ZHANG JL, SHEN Q, WANG N, et al. Values of serum 7 microRNAs alone or in combination with α-fetoprotein in diagnosing hepatocellular carcinoma[J]. Acad J Nav Med Univ, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648. 张敬磊, 沈强, 王能, 等. 血清7种微RNA单独或联合甲胎蛋白检测对肝细胞癌的诊断价值[J]. 海军军医大学学报, 2023, 44( 5): 636- 639. DOI: 10.16781/j.cn31-2187/r.20220648.

Relative Articles

[1]	Junjun WANG, Xiaobo CAI, Lungen LU. Association between bile acids and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1166-1171. doi: 10.3969/j.issn.1001-5256.2023.05.026
[2]	Shiyang LIANG, Qiang LIN, Junliang SONG, Jingjie WANG. Role of bile acids in cirrhosis-related cardiomyopathy[J]. Journal of Clinical Hepatology, 2022, 38(10): 2383-2386. doi: 10.3969/j.issn.1001-5256.2022.10.035
[3]	Huangbin ZHANG, Yehong YAN, Hao WAN, Jiansheng XIAO, Shitao ZHAO, Weiqiang ZENG. Primary liver cancer with prostate metastasis: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1427-1428. doi: 10.3969/j.issn.1001-5256.2021.06.042
[4]	Jiachao ZHANG, Zhensheng ZHANG, Pingping CHEN, Rong TANG, Yongchao ZENG, Qizhao LI. Complete remission after comprehensive treatment of lung metastases following liver cancer surgery: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1432-1434. doi: 10.3969/j.issn.1001-5256.2021.06.044
[5]	Zherui LIU, Xiaodong JIA, Yinying LU. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. Journal of Clinical Hepatology, 2021, 37(3): 690-694. doi: 10.3969/j.issn.1001-5256.2021.03.038
[6]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[7]	YE QingLing, WANG MingGang, MAO DeWen, JIANG HaiNan. Role of bile acids in enterohepatic circulation and mechanism of action of traditional Chinese medicine in regulating bile acids[J]. Journal of Clinical Hepatology, 2020, 36(11): 2617-2620. doi: 10.3969/j.issn.1001-5256.2020.11.050
[8]	Zhang CongQi, Wu Hao, Xing MingXuan, Wang Wu. Mixed adenoneuroendocrine carcinoma of the gallbladder with hepatic metastasis: A case report[J]. Journal of Clinical Hepatology, 2020, 36(3): 657-658. doi: 10.3969/j.issn.1001-5256.2020.03.039
[9]	Zhu ZeMin, Xie ZhiQin, Zhao ZhiJian, Li Bin, Li HongXia, Tang CaiXi. Renal clear cell carcinoma with large hepatocellular carcinoma metastasis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(5): 1084-1085. doi: 10.3969/j.issn.1001-5256.2019.05.032
[10]	Chen RuiLing, Ma Xiong. Pathogenesis of cholestasis-induced liver fibrosis and thoughts for blockade[J]. Journal of Clinical Hepatology, 2019, 35(2): 247-251. doi: 10.3969/j.issn.1001-5256.2019.02.002
[11]	Wu HuiLi, Zheng SuJun, Duan ZhongPing. Route of metastasis of primary hepatic carcinoma from the perspective of anatomy[J]. Journal of Clinical Hepatology, 2017, 33(10): 2009-2015. doi: 10.3969/j.issn.1001-5256.2017.10.035
[13]	Lu DongYan, Ye XiaoWei. One case of primary hepatic carcinoid tumor with multiple metastases[J]. Journal of Clinical Hepatology, 2016, 32(1): 155-156. doi: 10.3969/j.issn.1001-5256.2016.01.031
[14]	Sun Jing, Po JunJie, Fan YuZe, He WeiPing, Li Huan, Sun YingZhe, Wang Hui, Duan XueZhang. Effect of stereotactic body radiotherapy versus intensity-modulated radiotherapy in primary liver cancer patients with secondary malignant tumor of vertebra[J]. Journal of Clinical Hepatology, 2016, 32(6): 1135-1138. doi: 10.3969/j.issn.1001-5256.2016.06.023
[15]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[16]	Wang XiaoRen, Yan BingZhu, Yang BaoShan. The prognostic assessment of model for end-stage liver disease (MELD) and total bile acids in patients with subacute liver failure[J]. Journal of Clinical Hepatology, 2011, 27(6): 638-640.
[17]	Song MinNing, Fan RongHua, Huang WenQi, Min Feng. The analysis of turnover among serum total bile acid levels in hepatitis during pregnancy[J]. Journal of Clinical Hepatology, 2011, 27(3): 309-311.
[19]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (585) PDF downloads(39)

Differences and application value of plasma bile acids in tumors of the liver

DOI: 10.12449/JCH241018

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Differences and application value of plasma bile acids in tumors of the liver

DOI: 10.12449/JCH241018

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content